Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase Zeta Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer.

Abstract

Studies of diacylglycerol kinase ζ (DGKζ) in DGKζ knockout mice have revealed its role as an intracellular immune checkpoint in T cells. Although enhancing antitumor immunity by pharmacological inhibition of DGKζ is desirable, selective DGKζ inhibitors for clinical use remain largely unexplored. Here, we report a novel, small-molecule, DGKζ inhibitor, ASP1570, which is currently under phase 1 development (NCT05083481), and characterize its effect on potential resistance mechanisms against approved immune checkpoint inhibitors in multiple immunosuppressive conditions: not only TGF-β, PGE2, adenosine, PD-1, but also CTLA-4 and TIGIT. Firstly, our findings indicated that ASP1570 exhibited an inhibitory effect on the kinase activity of DGKζ. Unexpectedly, we observed that DGKζ protein was degraded in cells treated with ASP1570 in a proteasome-dependent manner. ASP1570 enhanced T-cell activation with increased diacylglycerol downstream signaling and released anergic T cells from their hyporesponsive state. Further, ASP1570 restored T-cell functions suppressed by multiple immunosuppressive signals (TGF-β, PGE2, adenosine, PD-1, CTLA-4, and TIGIT) and induced tumor growth inhibition in 2 types of syngeneic mouse models: anti-PD-1-antibody-sensitive MC38 and anti-PD-1-antibody-insensitive B16F1/F10. The antitumor efficacy of ASP1570 was cancelled by CD8+ T-cell depletion, indicating that its antitumor effect depends on CD8+ cytotoxic T-cell activation. Collectively, ASP1570 potentially improves antitumor efficacy in both anti-PD-1-therapy-resistant and anti-PD-1-therapy-responsive tumors by overcoming multiple immunosuppressive signals.